Predict your next investment

R&G PharmaStudies company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
rg-pharma.com

See what CB Insights has to offer

Investments

1

Partners & Customers

1

About R&G PharmaStudies

R&G PharmaStudies is a contract research organization. The company provides clinical research, data management, and analysis services.

R&G PharmaStudies Headquarter Location

19 West Chegongzhuang Road Huatong Plaza, North Tower, Building B, Floor 11

Beijing, 10048,

China

+(86)010-8801 8650

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

R&G PharmaStudies Investments

1 Investments

R&G PharmaStudies has made 1 investments. Their latest investment was in Genfleet as part of their Series B on March 3, 2020.

CBI Logo

R&G PharmaStudies Investments Activity

investments chart

R&G PharmaStudies Partners & Customers

1 Partners and customers

R&G PharmaStudies has 1 strategic partners and customers. R&G PharmaStudies recently partnered with ArisGlobal, and DeltaMed on April 4, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

4/16/2018

Vendor, and Client

ArisGlobal, and DeltaMed

United States, and China

ArisGlobal Introduces LifeSphere Safety MultiVigilance™ Pharmacovigilance Solution for China

`` We are very pleased to support Center for Drug Evaluation with LifeSphere Safety MultiVigilance and we look forward to supporting all our customers and partners in China to help them comply with the new CFDA regulations for reporting safety data from clinical trials . ''

4

Date

4/16/2018

Type

Vendor, and Client

Business Partner

ArisGlobal, and DeltaMed

Country

United States, and China

News Snippet

ArisGlobal Introduces LifeSphere Safety MultiVigilance™ Pharmacovigilance Solution for China

`` We are very pleased to support Center for Drug Evaluation with LifeSphere Safety MultiVigilance and we look forward to supporting all our customers and partners in China to help them comply with the new CFDA regulations for reporting safety data from clinical trials . ''

Sources

4

R&G PharmaStudies Team

1 Team Member

R&G PharmaStudies has 1 team member, including former Chief Financial Officer, Xiaoyan Tang.

Name

Work History

Title

Status

Xiaoyan Tang

Chief Financial Officer

Former

Name

Xiaoyan Tang

Work History

Title

Chief Financial Officer

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.